Kevan Shokhat

Kevan Shokhat is a scientific co-founder of Nested Therapeutics. He is currently an Investigator of the Howard Hughes Medical Institute, Professor in the Department of Cellular and Molecular Pharmacology at UCSF and a Professor of Chemistry at UC Berkeley. He was inducted into the National Academy of Sciences (2010), the Institute of Medicine (2011), and the American Academy of Arts and Sciences (2011). His lab is most well-known for drugging the “undruggable” oncogene K-Ras (G12C) in 2013. K-Ras was the first human oncogene to be discovered in 1982 and remained undrugged until work from the Shokat lab at UCSF. In May of 2021, the drug sotorasib which binds to the same pocket on K-Ras (G12C) was approved for the treatment of lung cancer patients with this mutation. Recently his lab has applied covalent somatic cysteine targeting drugs to reactive the tumor suppressor p53 (Y220C) mutant. Kevan has been a co-founder of a number companies from their inception to public offering or acquisition: Intellikine (acquired by Takeda), Araxes (acquired by Janssen), eFFECTOR Pharmaceuticals (stock symbol: EFTR), Erasca (stock symbol: ERAS), Kura Oncology (stock symbol: KURA), and Revolution Medicines (stock symbol: RVMD). He is a co-founder of several currently private companies. Kevan earned his Ph.D. from the University of California, Berkeley.